FDA to Revise GMPs for Components to Protect Supply Chain

The FDA is revising good manufacturing practice (GMP) regulations for incoming raw materials to help industry secure the pharmaceutical supply chain against economically motivated adulteration. Revised regulations will significantly improve the control over suppliers, Deb Autor, director of CDER’s Office of Compliance, said Monday at the 2010 PDA/FDA Pharmaceutical Supply Chain Workshop in Bethesda, Md. There is no timeline for the revisions, but they are under way, she said.
Drug Industry Daily